If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X November 2014 • emjreviews.com<br /> INSIDE<br /> Review of<br /> ESMO 2014<br /> ILC 2014<br /> Madrid, Spain<br /> London, UK<br /> A First-Line BRAF Inhibitor<br /> TAFINLAR is indicated in monotherapy for the treatment of adult patients<br /> with unresectable or metastatic melanoma with a BRAF V600 mutation<br /> Before taking TAFINLAR, patients must have confirmation of tumour BRAF V600 mutation using a validated test<br /> Prescribing Information<br /> (Please refer to full SmPC before prescribing)<br /> Tafinlar ® (dabrafenib) 50mg and 75mg capsules. Each capsule contains<br /> dabrafenib mesilate, equivalent to 50mg and 75mg of dabrafenib, respectively.<br /> Indication In monotherapy for adults with unresectable or metastatic melanoma<br /> with a BRAF V600 mutation. Dosage and administration Before taking<br /> dabrafenib, patients must have confir<a title="EMJ Oncology 2014 page 1" href="http://viewer.zmags.com/publication/61d35aa7?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 2014 page 2" href="http://viewer.zmags.com/publication/61d35aa7?page=2"> A First-Line BRAF Inhibitor TAFINLAR </a> <a title="EMJ Oncology 2014 page 3" href="http://viewer.zmags.com/publication/61d35aa7?page=3"> Treatment with TAFINLAR was proven to significantl</a> <a title="EMJ Oncology 2014 page 4" href="http://viewer.zmags.com/publication/61d35aa7?page=4"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Oncology 2014 page 5" href="http://viewer.zmags.com/publication/61d35aa7?page=5"> ONCOLOGY IMMUNOTHERAPY OF CANCER: TOWARDS A NEW</a> <a title="EMJ Oncology 2014 page 6" href="http://viewer.zmags.com/publication/61d35aa7?page=6"> Bosulif® (bosutinib): Meeting an unmet need in a</a> <a title="EMJ Oncology 2014 page 7" href="http://viewer.zmags.com/publication/61d35aa7?page=7"> Editorial Board Oncology Editor-in-Chief: Prof</a> <a title="EMJ Oncology 2014 page 8" href="http://viewer.zmags.com/publication/61d35aa7?page=8"> Precise Efficient Versatile Proven as </a> <a title="EMJ Oncology 2014 page 9" href="http://viewer.zmags.com/publication/61d35aa7?page=9"> Welcome Oncology is a tough and demanding discipl</a> <a title="EMJ Oncology 2014 page 10" href="http://viewer.zmags.com/publication/61d35aa7?page=10"> SUBSCRIBE TO THE EMJ NEWSLETTER www.news.emjre</a> <a title="EMJ Oncology 2014 page 11" href="http://viewer.zmags.com/publication/61d35aa7?page=11"> Foreword Prof Ross Abrams Hendrickson Prof</a> <a title="EMJ Oncology 2014 page 12" href="http://viewer.zmags.com/publication/61d35aa7?page=12"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 13" href="http://viewer.zmags.com/publication/61d35aa7?page=13"> Welcome to the European Medical Journal review of</a> <a title="EMJ Oncology 2014 page 14" href="http://viewer.zmags.com/publication/61d35aa7?page=14"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 15" href="http://viewer.zmags.com/publication/61d35aa7?page=15"> delegates’ minds since the foundation of th</a> <a title="EMJ Oncology 2014 page 16" href="http://viewer.zmags.com/publication/61d35aa7?page=16"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 17" href="http://viewer.zmags.com/publication/61d35aa7?page=17"> Antibody-based bladder cancer therapy shows promi</a> <a title="EMJ Oncology 2014 page 18" href="http://viewer.zmags.com/publication/61d35aa7?page=18"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 19" href="http://viewer.zmags.com/publication/61d35aa7?page=19"> Plethora of positives in supportive cancer care S</a> <a title="EMJ Oncology 2014 page 20" href="http://viewer.zmags.com/publication/61d35aa7?page=20"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 21" href="http://viewer.zmags.com/publication/61d35aa7?page=21"> No time for gaps in cancer-drug approval LIFE-EXT</a> <a title="EMJ Oncology 2014 page 22" href="http://viewer.zmags.com/publication/61d35aa7?page=22"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 23" href="http://viewer.zmags.com/publication/61d35aa7?page=23"> Breast cancer faces new foe ATTACKS on HER2-posi</a> <a title="EMJ Oncology 2014 page 24" href="http://viewer.zmags.com/publication/61d35aa7?page=24"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 25" href="http://viewer.zmags.com/publication/61d35aa7?page=25"> Combined therapies enhance patient survival MAGNI</a> <a title="EMJ Oncology 2014 page 26" href="http://viewer.zmags.com/publication/61d35aa7?page=26"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 27" href="http://viewer.zmags.com/publication/61d35aa7?page=27"> Added artillery treatment target. According to Dr</a> <a title="EMJ Oncology 2014 page 28" href="http://viewer.zmags.com/publication/61d35aa7?page=28"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 29" href="http://viewer.zmags.com/publication/61d35aa7?page=29"> Mutations mar clinical comforts of anti-HER2 drug</a> <a title="EMJ Oncology 2014 page 30" href="http://viewer.zmags.com/publication/61d35aa7?page=30"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 31" href="http://viewer.zmags.com/publication/61d35aa7?page=31"> Melanoma tumours beware of nivolumab SUPERIOR res</a> <a title="EMJ Oncology 2014 page 32" href="http://viewer.zmags.com/publication/61d35aa7?page=32"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 33" href="http://viewer.zmags.com/publication/61d35aa7?page=33"> Tumour-infiltrating lymphocytes: treatment and pro</a> <a title="EMJ Oncology 2014 page 34" href="http://viewer.zmags.com/publication/61d35aa7?page=34"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 35" href="http://viewer.zmags.com/publication/61d35aa7?page=35"> Strings added to bow in prostate cancer crusade M</a> <a title="EMJ Oncology 2014 page 36" href="http://viewer.zmags.com/publication/61d35aa7?page=36"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 37" href="http://viewer.zmags.com/publication/61d35aa7?page=37"> Gastric cancer meets its match “We are enco</a> <a title="EMJ Oncology 2014 page 38" href="http://viewer.zmags.com/publication/61d35aa7?page=38"> ESMO ANNUAL CONGRESS 2014 IFEMA – FERIA DE MADRID</a> <a title="EMJ Oncology 2014 page 39" href="http://viewer.zmags.com/publication/61d35aa7?page=39"> Navigate the uncertainty of relapsed/ refractory </a> <a title="EMJ Oncology 2014 page 40" href="http://viewer.zmags.com/publication/61d35aa7?page=40"> SEQUENTIAL ANDROGEN RECEPTOR PATHWAY INHIBITOR I</a> <a title="EMJ Oncology 2014 page 41" href="http://viewer.zmags.com/publication/61d35aa7?page=41"> important question for the clinician. One of the </a> <a title="EMJ Oncology 2014 page 42" href="http://viewer.zmags.com/publication/61d35aa7?page=42"> Table 1: Main findings from key clinical studies o</a> <a title="EMJ Oncology 2014 page 43" href="http://viewer.zmags.com/publication/61d35aa7?page=43"> Table 1 continued. Study Population Active th</a> <a title="EMJ Oncology 2014 page 44" href="http://viewer.zmags.com/publication/61d35aa7?page=44"> Efstathiou et al.24 recently reported the r</a> <a title="EMJ Oncology 2014 page 45" href="http://viewer.zmags.com/publication/61d35aa7?page=45"> Median time to PSA progression was 17.4 weeks and</a> <a title="EMJ Oncology 2014 page 46" href="http://viewer.zmags.com/publication/61d35aa7?page=46"> approved AR-targeted agents, and that patients wi</a> <a title="EMJ Oncology 2014 page 47" href="http://viewer.zmags.com/publication/61d35aa7?page=47"> 27. Mostaghel EA et al. Resistance to CYP17A1 in</a> <a title="EMJ Oncology 2014 page 48" href="http://viewer.zmags.com/publication/61d35aa7?page=48"> UNMET MEDICAL NEEDS IN NON-SMALL-CELL LUNG CANCER</a> <a title="EMJ Oncology 2014 page 49" href="http://viewer.zmags.com/publication/61d35aa7?page=49"> offered a therapeutic alternative for patients wi</a> <a title="EMJ Oncology 2014 page 50" href="http://viewer.zmags.com/publication/61d35aa7?page=50"> The main problem is that STAT3 signalling is not </a> <a title="EMJ Oncology 2014 page 51" href="http://viewer.zmags.com/publication/61d35aa7?page=51"> growth factors, such as EGF, HGF, or Gas6.</a> <a title="EMJ Oncology 2014 page 52" href="http://viewer.zmags.com/publication/61d35aa7?page=52"> SHP2-dependent ERK activation signal pathway </a> <a title="EMJ Oncology 2014 page 53" href="http://viewer.zmags.com/publication/61d35aa7?page=53"> 15. Sordella R et al. Gefitinib-sensitizing EGFR m</a> <a title="EMJ Oncology 2014 page 54" href="http://viewer.zmags.com/publication/61d35aa7?page=54"> WOMEN AND LUNG CANCER: LITERATURE ASSUMP</a> <a title="EMJ Oncology 2014 page 55" href="http://viewer.zmags.com/publication/61d35aa7?page=55"> a publication had to fulfil the following criteria</a> <a title="EMJ Oncology 2014 page 56" href="http://viewer.zmags.com/publication/61d35aa7?page=56"> oestrogen receptors (ERs) are present in bo</a> <a title="EMJ Oncology 2014 page 57" href="http://viewer.zmags.com/publication/61d35aa7?page=57"> 140 120 100 80 60 Number of estimated case</a> <a title="EMJ Oncology 2014 page 58" href="http://viewer.zmags.com/publication/61d35aa7?page=58"> after LC. Thus, compared to the historical data, </a> <a title="EMJ Oncology 2014 page 59" href="http://viewer.zmags.com/publication/61d35aa7?page=59"> different disease per se; this remains to be clar</a> <a title="EMJ Oncology 2014 page 60" href="http://viewer.zmags.com/publication/61d35aa7?page=60"> Endogenous Hormones A meta-analysis by Zhang et a</a> <a title="EMJ Oncology 2014 page 61" href="http://viewer.zmags.com/publication/61d35aa7?page=61"> to the historical data, recent publications confir</a> <a title="EMJ Oncology 2014 page 62" href="http://viewer.zmags.com/publication/61d35aa7?page=62"> modulate tumor growth and metabolism of lung ad</a> <a title="EMJ Oncology 2014 page 63" href="http://viewer.zmags.com/publication/61d35aa7?page=63"> RITUXIMAB AND OTHER NEW ANTI-CD20 MABS FOR NON-HO</a> <a title="EMJ Oncology 2014 page 64" href="http://viewer.zmags.com/publication/61d35aa7?page=64"> with chemotherapy and radiotherapy develop se</a> <a title="EMJ Oncology 2014 page 65" href="http://viewer.zmags.com/publication/61d35aa7?page=65"> aggressive NHL (MabThera International Trial); 82</a> <a title="EMJ Oncology 2014 page 66" href="http://viewer.zmags.com/publication/61d35aa7?page=66"> RTX-Containing Radioimmunoconjugates Immunoconjug</a> <a title="EMJ Oncology 2014 page 67" href="http://viewer.zmags.com/publication/61d35aa7?page=67"> In a further Phase II study, OFA was evaluated in</a> <a title="EMJ Oncology 2014 page 68" href="http://viewer.zmags.com/publication/61d35aa7?page=68"> Obinutuzumab is currently being evaluated in</a> <a title="EMJ Oncology 2014 page 69" href="http://viewer.zmags.com/publication/61d35aa7?page=69"> 16. Kitson SL et al. Radionuclide antibody- conju</a> <a title="EMJ Oncology 2014 page 70" href="http://viewer.zmags.com/publication/61d35aa7?page=70"> FUNDAMENTAL PRINCIPLES OF RAISING AN A</a> <a title="EMJ Oncology 2014 page 71" href="http://viewer.zmags.com/publication/61d35aa7?page=71"> move towards immune organs such as tumour- draini</a> <a title="EMJ Oncology 2014 page 72" href="http://viewer.zmags.com/publication/61d35aa7?page=72"> concerning clinical efficacy and a prolonged</a> <a title="EMJ Oncology 2014 page 73" href="http://viewer.zmags.com/publication/61d35aa7?page=73"> the registration of Provenge.23 A variant from th</a> <a title="EMJ Oncology 2014 page 74" href="http://viewer.zmags.com/publication/61d35aa7?page=74"> While treatment tolerance was excellent, patient </a> <a title="EMJ Oncology 2014 page 75" href="http://viewer.zmags.com/publication/61d35aa7?page=75"> CONCLUSIONS AND PERSPECTIVES While many isolat</a> <a title="EMJ Oncology 2014 page 76" href="http://viewer.zmags.com/publication/61d35aa7?page=76"> IMMUNOTHERAPY OF CANCER: TOWARDS A NEW ERA </a> <a title="EMJ Oncology 2014 page 77" href="http://viewer.zmags.com/publication/61d35aa7?page=77"> These antigens are mostly derived from tumour- as</a> <a title="EMJ Oncology 2014 page 78" href="http://viewer.zmags.com/publication/61d35aa7?page=78"> by the co-stimulatory molecule CD28 on the T cell</a> <a title="EMJ Oncology 2014 page 79" href="http://viewer.zmags.com/publication/61d35aa7?page=79"> MDX-1105 was well tolerated and induced fewer imm</a> <a title="EMJ Oncology 2014 page 80" href="http://viewer.zmags.com/publication/61d35aa7?page=80"> and metastasis formation may be highly hostile fo</a> <a title="EMJ Oncology 2014 page 81" href="http://viewer.zmags.com/publication/61d35aa7?page=81"> The latter may be induced at the tumour c</a> <a title="EMJ Oncology 2014 page 82" href="http://viewer.zmags.com/publication/61d35aa7?page=82"> of interferon alfa 2b versus observation in patie</a> <a title="EMJ Oncology 2014 page 83" href="http://viewer.zmags.com/publication/61d35aa7?page=83"> RADIOTHERAPY FOR BREAST CANCER: HOW CAN IT BEN</a> <a title="EMJ Oncology 2014 page 84" href="http://viewer.zmags.com/publication/61d35aa7?page=84"> change in target volume from the whole breast to </a> <a title="EMJ Oncology 2014 page 85" href="http://viewer.zmags.com/publication/61d35aa7?page=85"> • Contouring of all target volumes and relevant</a> <a title="EMJ Oncology 2014 page 86" href="http://viewer.zmags.com/publication/61d35aa7?page=86"> Tangential radiation beam Field-in- fiel</a> <a title="EMJ Oncology 2014 page 87" href="http://viewer.zmags.com/publication/61d35aa7?page=87"> a bc Figure 2: Image guidance</a> <a title="EMJ Oncology 2014 page 88" href="http://viewer.zmags.com/publication/61d35aa7?page=88"> Radiation beams Posterior beam edge F</a> <a title="EMJ Oncology 2014 page 89" href="http://viewer.zmags.com/publication/61d35aa7?page=89"> Acknowledgements The authors would like to thank </a> <a title="EMJ Oncology 2014 page 90" href="http://viewer.zmags.com/publication/61d35aa7?page=90"> imaging devices: a review and histori</a> <a title="EMJ Oncology 2014 page 91" href="http://viewer.zmags.com/publication/61d35aa7?page=91"> MANAGEMENT OF PATIENTS WITH </a> <a title="EMJ Oncology 2014 page 92" href="http://viewer.zmags.com/publication/61d35aa7?page=92"> exhibits platelet-derived growth factor recep</a> <a title="EMJ Oncology 2014 page 93" href="http://viewer.zmags.com/publication/61d35aa7?page=93"> SURGICAL RESECTION Rationale for Surgery Surgical</a> <a title="EMJ Oncology 2014 page 94" href="http://viewer.zmags.com/publication/61d35aa7?page=94"> A B C Figure 2: A) A 30-year-old </a> <a title="EMJ Oncology 2014 page 95" href="http://viewer.zmags.com/publication/61d35aa7?page=95"> occurred within 2 cm of the original tumour site </a> <a title="EMJ Oncology 2014 page 96" href="http://viewer.zmags.com/publication/61d35aa7?page=96"> 354 biopsies taken from fluorescing areas showed t</a> <a title="EMJ Oncology 2014 page 97" href="http://viewer.zmags.com/publication/61d35aa7?page=97"> These prospective data are supported by a r</a> <a title="EMJ Oncology 2014 page 98" href="http://viewer.zmags.com/publication/61d35aa7?page=98"> a supplemental analysis from the randomiz</a> <a title="EMJ Oncology 2014 page 99" href="http://viewer.zmags.com/publication/61d35aa7?page=99"> 75. Batchelor TT et al. Phase II study of cedir</a> <a title="EMJ Oncology 2014 page 100" href="http://viewer.zmags.com/publication/61d35aa7?page=100"> STATE-OF-THE-ART TREATMENT IN CASTRATIO</a> <a title="EMJ Oncology 2014 page 101" href="http://viewer.zmags.com/publication/61d35aa7?page=101"> Cytotoxic Chemotherapy Docetaxel Docetaxel was th</a> <a title="EMJ Oncology 2014 page 102" href="http://viewer.zmags.com/publication/61d35aa7?page=102"> radiographic progression free survival (r</a> <a title="EMJ Oncology 2014 page 103" href="http://viewer.zmags.com/publication/61d35aa7?page=103"> Both abiraterone and enzalutamide hav</a> <a title="EMJ Oncology 2014 page 104" href="http://viewer.zmags.com/publication/61d35aa7?page=104"> Denosumab, a fully human monoclonal antibody with</a> <a title="EMJ Oncology 2014 page 105" href="http://viewer.zmags.com/publication/61d35aa7?page=105"> 682X.127824. [Epub ahead of print]. 7. Sweeney C </a> <a title="EMJ Oncology 2014 page 106" href="http://viewer.zmags.com/publication/61d35aa7?page=106"> ADVERTORIAL RAPIDPLAN™: VARIAN’S NEXT</a> <a title="EMJ Oncology 2014 page 107" href="http://viewer.zmags.com/publication/61d35aa7?page=107"> ADVERTORIAL Systems, Palo Alto, CA, USA) startin</a> <a title="EMJ Oncology 2014 page 108" href="http://viewer.zmags.com/publication/61d35aa7?page=108"> ADVERTORIAL </a> <a title="EMJ Oncology 2014 page 109" href="http://viewer.zmags.com/publication/61d35aa7?page=109"> ADVERTORIAL Role in Radiation Oncology Knowledge</a> <a title="EMJ Oncology 2014 page 110" href="http://viewer.zmags.com/publication/61d35aa7?page=110"> WHAT’S NEW One test diagnoses all freeimages.com</a> <a title="EMJ Oncology 2014 page 111" href="http://viewer.zmags.com/publication/61d35aa7?page=111"> ONCOLOGY Cancer therapy evolution: self-assemblin</a> <a title="EMJ Oncology 2014 page 112" href="http://viewer.zmags.com/publication/61d35aa7?page=112"> WHAT’S NEW Tumours: the key “Based on the info</a> <a title="EMJ Oncology 2014 page 113" href="http://viewer.zmags.com/publication/61d35aa7?page=113"> ONCOLOGY Long-anticipated cancer detection techni</a> <a title="EMJ Oncology 2014 page 114" href="http://viewer.zmags.com/publication/61d35aa7?page=114"> WHAT’S NEW New genetic risk markers for pancreati</a> <a title="EMJ Oncology 2014 page 115" href="http://viewer.zmags.com/publication/61d35aa7?page=115"> ONCOLOGY Vasectomy </a> <a title="EMJ Oncology 2014 page 116" href="http://viewer.zmags.com/publication/61d35aa7?page=116"> WHAT’S NEW Pelvic examinations: causing more harm</a> <a title="EMJ Oncology 2014 page 117" href="http://viewer.zmags.com/publication/61d35aa7?page=117"> ONCOLOGY Breast cancer 430 will die from the illn</a> <a title="EMJ Oncology 2014 page 118" href="http://viewer.zmags.com/publication/61d35aa7?page=118"> WHAT’S NEW Promoting cancer cell suicide </a> <a title="EMJ Oncology 2014 page 119" href="http://viewer.zmags.com/publication/61d35aa7?page=119"> ONCOLOGY New imaging technique for neuroblastoma </a> <a title="EMJ Oncology 2014 page 120" href="http://viewer.zmags.com/publication/61d35aa7?page=120"> WHAT’S NEW War of words over emerging prostate ca</a> <a title="EMJ Oncology 2014 page 121" href="http://viewer.zmags.com/publication/61d35aa7?page=121"> From a host of fifteen therapeutic areas, EUROPEAN</a> <a title="EMJ Oncology 2014 page 122" href="http://viewer.zmags.com/publication/61d35aa7?page=122"> Featured Suppliers Oncology Pursuing a goal of </a> <a title="EMJ Oncology 2014 page 123" href="http://viewer.zmags.com/publication/61d35aa7?page=123"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Oncology 2014 page 124" href="http://viewer.zmags.com/publication/61d35aa7?page=124"> Buyer’s Guide & Societies Exhibitors • AGENDIA,</a> <a title="EMJ Oncology 2014 page 125" href="http://viewer.zmags.com/publication/61d35aa7?page=125"> • SIRTEX MEDICAL EUROPE GMBH • SOTIO A.S. • SYS</a> <a title="EMJ Oncology 2014 page 126" href="http://viewer.zmags.com/publication/61d35aa7?page=126"> UPCOMING EVENTS Union for International Cancer C</a> <a title="EMJ Oncology 2014 page 127" href="http://viewer.zmags.com/publication/61d35aa7?page=127"> ONCOLOGY 14th St. Gallen Breast Cancer Conferenc</a> <a title="EMJ Oncology 2014 page 128" href="http://viewer.zmags.com/publication/61d35aa7?page=128"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS PUBLI</a>